-
Sector Analysis
COVID-19: Contract Pharmaceutical Development and Manufacturing Relationships
This report examines contract manufacturing agreements for vaccines and therapies targeting COVID-19. It reports that there are more than 1,000 vaccines and therapies in development for COVID-19, and 36 vaccines and therapies approved (or granted emergency use authorization) for COVID-19 (as of report publication). At the beginning of the pandemic, slightly more than half of these agreements were for vaccines; this proportion has risen and continues to rise, as several vaccines have proven their safety and efficacy, received approval, and...
-
Sector Analysis
Coronavirus Disease 2019 (COVID-19) Vaccines – Contract Development and Manufacturing Landscape
This expert trend report is a comprehensive look at the contract manufacturing landscape surrounding COVID-19 Vaccine in 2020, including analysis of pipeline drugs, clinical trials, CMO activity, Contract Manufacturing Service Agreements, and funding for manufacturing of COVID-19 Vaccines. It is a critical source for strategic planning efforts and will improve understanding of crucial components of the supply chain that will provide insights for supplier selection and management.
-
Sector Analysis
PharmaPoint: Hemophilia A and B – Global Drug Forecast and Market Analysis to 2026
Hemophilia A and B are rare recessive X-linked genetic deficiencies in the blood clotting factors VIII and IX, respectively, and are characterized by the failure of blood to form normal clots after damage to veins and tissue. In the 7MM, patients with severe forms of the disease are increasingly treated on a prophylactic basis rather than on demand after bleeds. The frequent prophylactic infusions of rFVIII or rFIX begin from the first one or two years of life, often continuing...
-
Sector Analysis
Competitor Landscape: Systemic Sclerosis (Scleroderma)
Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the Systemic Sclerosis (Scleroderma) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher
-
Sector Analysis
Competitor Landscape: HIV
Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the HIV market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher
-
Sector Analysis
Hemophilia A and B – Global Drug Forecast and Market Analysis to 2028
Hemophilia A and B are rare, genetic, X-linked deficiencies in the blood clotting factors VIII (FVIII) and IX (FIX), respectively. Patients can be categorized as mild, moderate or severe depending on the percentage of circulating FVIII or FIX in their blood. Patients can be treated either on-demand or prophylactically using plasma-derived or recombinant replacement factors, the current standard of care. Although these therapies are effective, they are associated with a great treatment burden. There is a significant unmet need for...
-
Product Insights
AIDS – Related Cancer Global Clinical Trials Review, H2, 2018
GlobalData's clinical trial report, “AIDS - Related Cancer Global Clinical Trials Review, H2, 2018" provides an overview of AIDS - Related Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on AIDS - Related Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
AIDS – Related Lymphoma Global Clinical Trials Review, H2, 2018
GlobalData's clinical trial report, “AIDS - Related Lymphoma Global Clinical Trials Review, H2, 2018" provides an overview of AIDS - Related Lymphoma clinical trials scenario. This report provides top line data relating to the clinical trials on AIDS - Related Lymphoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Hemophilia B Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Hemophilia B Global Clinical Trials Review, H2, 2016" provides an overview of Hemophilia B clinical trials scenario. This report provides top line data relating to the clinical trials on Hemophilia B. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Hemophilia A Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Hemophilia A Global Clinical Trials Review, H2, 2016" provides an overview of Hemophilia A clinical trials scenario. This report provides top line data relating to the clinical trials on Hemophilia A. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...